Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

  title={Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease},
  author={Marc S. Sabatine and Robert P. Giugliano and Anthony C. Keech and Narimon Honarpour and Stephen D. Wiviott and Sabina A. Murphy and Julia Kuder and Huei Wang and Thomas Liu and Scott M. Wasserman and Peter S Sever and Terje Rolf Pedersen},
  journal={The New England Journal of Medicine},
BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low‐density lipoprotein (LDL) cholesterol levels by approximately 60. [] Key Method Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections.

Figures and Tables from this paper

Evolocumab and clinical outcomes in patients with cardiovascular disease.
Patients of atherosclerotic cardiovascular disease will benefit from lowering of LDL cholesterol levels till 30 mg/dl, well below current treatment targets, according to FOURIER study.
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
PCSK9 inhibition and clinical cardiovascular outcomes in patients with atherosclerotic cardiovascular disease
PCSK9 inhibition is now already used in clinical practice in patients with familial hypercholesterolaemia in need of additional LDL cholesterol-lowering approaches and in patientsWith severely increased cardiovascular risk, where a novel molecular approach is pursued to inhibit PCSK9 expression in the liver by RNA interference using a modified PCSK 9 siRNA.
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
At its current list price of $14 523, the addition of evolocumab to standard background therapy in patients with atherosclerotic cardiovascular disease exceeds generally accepted cost-effectiveness thresholds.
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial.
The efficacy and safety of evolocumab are similar throughout a broad range of ages and in both men and women.
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
The addition of the PCSK9 inhibitor evolocumab to statin therapy improved clinical outcomes, with significant reductions in total PEP events, driven by decreases in myocardial infarction, stroke, and coronary revascularization.
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
The use of evolocumab monotherapy seems appropriate only for individuals deemed statin-intolerant despite attempting several statins, including those with familial hypercholesterolemia and/or established cardiovascular disease, who are already on statin therapy.
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.
Use of evolocumab robustly lowers LDL-C and is equally efficacious in lowering the risk of cardiovascular events and safe in Asians as it is in others.
Evolocumab for the treatment of hypercholesterolemia
The clinical outcome data and excellent tolerability profile clearly support the use of evolocumab in patients at high cardiovascular risk, including those with heterozygous or homozygous familial hypercholesterolemia, who are unable to achieve LDL-C targets with statins with or without other lipid-lowering drugs.
Inflammatory and Cholesterol Risk in the FOURIER Trial
The efficacy of evolocumab stratified by baseline high-sensitivity C-reactive protein (hsCRP) and the importance of inflammatory and residual cholesterol risk across the range of on-treatment LDL-C concentrations were explored.


Evolocumab and clinical outcomes in patients with cardiovascular disease
  • P. Hamilton
  • Biology, Medicine
    Annals of clinical biochemistry
  • 2017
The FOURIER trial sought to investigate the utility of PCSK9 inhibition in cardiovascular disease by randomizing 27,525 patients with a history of cardiovascular disease to evolocumab or placebo as additional lipid-lowering therapy, and found no observed effect on cardiovascular mortality when considered in isolation.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels and reduced the incidence of cardiovascular events in a prespecified but exploratory analysis.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels and there was evidence of a reduction in the rate of cardiovascular events.
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Among patients with angiographic coronary disease treated with statins, addition of evolocumab, compared with placebo, resulted in a greater decrease in PAV after 76 weeks of treatment, and further studies are needed to assess the effects of PCSK9 inhibition on clinical outcomes.
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high- dose atorVastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes, and lowering LDL cholesterol to levels below previous targets provided additional benefit.